Quantcast

Lumenis Aligns with Globally Renowned Urologists at AUA to Review Benign Prostatic Hyperplasia (BPH)

May 19, 2012

HoLEP attains rapid adoption and acceptance as the Proven Procedure for Treating BPH

Yokneam, Israel (PRWEB) May 19, 2012

Lumenis Ltd., the world’s largest medical laser company developing, manufacturing and distributing a broad range of medical lasers and sophisticated energy delivery equipment for surgical, aesthetic and ophthalmic applications, announces that it will feature distinguished speakers from around the globe who will share their insights into the latest advances in surgical management of Benign Prostatic Hyperplasia (BPH) and Ureteral Calculi utilizing the VersaPulse Holmium laser in Lumenis´ booth (#2331) at this year´s American Urological Association (AUA) annual meeting, May 19-22 in Atlanta, Georgia.

The physicians will discuss Holmium laser treatments with proven clinical outcomes, such as Holmium Laser Enucleation of the Prostate (HoLEP) and Holmium Laser Ablation of the Prostate (HoLAP). As reported in Journal of Urology, “HoLEP represents a successful, safe and durable treatment for the symptomatic enlarged prostate with lower recurrence rate on long-term follow-up.”(1) These BPH laser treatments offer proven outcomes and low long-term reoperation rates.(2)

“Lumenis 100 Watt laser is the only laser which can completely enucleate large prostate glands with precision and true depiction of anatomical capsule. All other lasers either vaporize the tissue or charring is produced that poorly defines the capsule and results in residual prostates especially in large glands,” stated Dr. Anil Kumar Varshney, Medical Director and Head of Endourology and Lithotripsy, R.G. Stone Urology & Laparoscopy Hospital, Delhi, India.

VersaPulse holmium treatments have a long history of proven efficacy with vast clinical evidence. The National Institute for Health and Clinical Excellence (NICE) in the United Kingdom issued a guideline adding HoLEP to their list of recommended treatment options for BPH.

“HoLEP is the most well researched and clinically proven treatment for BPH management. Lumenis is pleased to see that our VersaPulse holmium solution has made such a positive and significant impact in the treatment of HoLEP,” said Danny Albeck, Lumenis´ VP of Research & Development and Acting VP of the Surgical Division. “Leading physicians who we have trained on our technology and who have honed their skills thereafter have brought recognition to the HoLEP procedure as a best treatment choice for BPH for patients. Awareness of the economic value to the health system and proven positive results for patients only strengthens our commitment in furthering research and development efforts in this space.”

Topics presented at Lumenis´ Booth #2331 at the AUA will include:

  •     HoLEP: A Practical Guide to Overcoming the Learning Curve Presented by: Joel Funk, MD, Assistant Professor of Clinical Surgery University of Arizona Medical Center
  •     Surgical Management of BPH: Large glands & HoLEP vs. HoLAP Presented by: Anil Kumar Varshney, MD Medical Director & Head of Endourology and Lithotripsy, R.G. Stone Urology & Laparoscopy Hospital, Delhi, India
  •     Advances in the Management of Ureteral Calculi Presented by: Michael Lipkin, MD, Assistant Professor of Urology, Duke University Medical Center

For a complete list of speaker presentations and other Lumenis events, visit the Lumenis booth #2331 at the American Urology Association annual meeting or visit http://www.surgical.lumenis.com/aua2012 to pre-register, and be sure to come early as seating is limited.

About Lumenis

Lumenis, the world’s largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, ophthalmic and aesthetic applications, with more than 800 employees worldwide. Lumenis has 270 registered patents, over 260 FDA clearances, an installed base of over 30,000 systems and a presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning “Light of Life” highlighting the light, which is the basis of our technologies, used to enhance life. For more information about Lumenis and its products, please visit: http://www.lumenis.com.

For further information contact:

Julie Shafiki

Global Director, Marketing Communications

+972-4-9599113

+972-54-4991970

Julie.shafiki(at)lumenis(dot)com

Lumenis®, its logo and VersaPulse® P20 are trademarks or registered trademarks of the Lumenis Group of Companies.

(1) Holmium Laser Enucleation of the Prostate: Long-Term Durability of Clinical Outcomes and Complication Rates During 10 years of Follow-up. Elmansy, Hazem M., Kotb, Ahmed, Elhilali, Mostafa M., Jnl of Uro, 2011 Nov Vol 186 p1972-176

(2) Long-term Results of High-power Holmium Laser Vaporization (Ablation) of the Prostate, Tan A., et al. BJU International 92:707-9, 2003

HoLEP vs. TURP Reoperation Rates and Cost Effectiveness, Gilling PJ presented material at WCE and AUA 2009

Holmium Laser Enucleation of the Prostate; Results at 6 Years, Gilling PJ, Aho, TF, Frampton CM, et al. Eur Urol 2008 Apr:53(4):744-9

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/5/prweb9525312.htm


Source: prweb



comments powered by Disqus